• Je něco špatně v tomto záznamu ?

NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours

M. Indrová, J. Símová, J. Bieblová, J. Bubeník, M. Reinis

. 2011 ; 25 (1) : 281-288.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027262

Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape T-cell mediated immune responses. In this study, we examined the role of different immune cell lineages in the development of immunity against tumours of the same aetiology but with different MHC class I expression. In vivo depletion of CD8+ cells, but not of CD4+ or NK1.1+ cells in the immunization period resulted in complete elimination of the protective effects of immunization with irradiated TC-1 cells (MHC class I-positive cell line) against the TC-1 tumour challenge. After immunization with irradiated TC-1/A9 or with MK16 tumour cells (MHC class I-deficient sublines) a remarkable dependence on the presence of NK1.1+ cells was observed, while the tumour growth inhibition after CD4+ or CD8+ depletion was not efficient. Cytotoxic activity induced by TC-1 cell immunization was significantly abrogated in the CD8+ and CD4+ but not NK1.1+ cell-depleted mice, as compared to the immunized only controls. After MK16 or TC-1/A9 cell immunization, NK1.1+ but not CD8+ and CD4+ cell-depleted mice displayed significant reduction of specific cytotoxicity. Mice immunized with TC-1 cells showed similar percentage of IFNγ producing cells in CD8+, CD4+ and NK1.1+ cell populations. On the other hand, the highest proportion of IFNγ producing cells after immunization with TC-1/A9 or MK16 cells was concentrated into the NK1.1-positive spleen cell population. Our data demonstrate that the development of immunity against MHC class I-deficient tumours is highly dependent on the activity NK1.1+ cell population.

000      
00000naa a2200000 a 4500
001      
bmc12027262
003      
CZ-PrNML
005      
20160324174317.0
007      
ta
008      
120816s2011 gr f 000 0#eng||
009      
AR
035    __
$a (PubMed)21109988
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Indrová, Marie $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. marie.indrova@img.cas.cz
245    10
$a NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours / $c M. Indrová, J. Símová, J. Bieblová, J. Bubeník, M. Reinis
520    9_
$a Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape T-cell mediated immune responses. In this study, we examined the role of different immune cell lineages in the development of immunity against tumours of the same aetiology but with different MHC class I expression. In vivo depletion of CD8+ cells, but not of CD4+ or NK1.1+ cells in the immunization period resulted in complete elimination of the protective effects of immunization with irradiated TC-1 cells (MHC class I-positive cell line) against the TC-1 tumour challenge. After immunization with irradiated TC-1/A9 or with MK16 tumour cells (MHC class I-deficient sublines) a remarkable dependence on the presence of NK1.1+ cells was observed, while the tumour growth inhibition after CD4+ or CD8+ depletion was not efficient. Cytotoxic activity induced by TC-1 cell immunization was significantly abrogated in the CD8+ and CD4+ but not NK1.1+ cell-depleted mice, as compared to the immunized only controls. After MK16 or TC-1/A9 cell immunization, NK1.1+ but not CD8+ and CD4+ cell-depleted mice displayed significant reduction of specific cytotoxicity. Mice immunized with TC-1 cells showed similar percentage of IFNγ producing cells in CD8+, CD4+ and NK1.1+ cell populations. On the other hand, the highest proportion of IFNγ producing cells after immunization with TC-1/A9 or MK16 cells was concentrated into the NK1.1-positive spleen cell population. Our data demonstrate that the development of immunity against MHC class I-deficient tumours is highly dependent on the activity NK1.1+ cell population.
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny Ly $x imunologie $7 D000950
650    _2
$a CD4-pozitivní T-lymfocyty $x imunologie $7 D015496
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
650    _2
$a protinádorové vakcíny $x imunologie $7 D019496
650    _2
$a separace buněk $7 D002469
650    _2
$a ELISA $7 D004797
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a MHC antigeny I. třídy $x imunologie $7 D015395
650    _2
$a lidský papilomavirus 16 $7 D052162
650    _2
$a buňky NK $x imunologie $7 D007694
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a lektinové receptory NK-buněk - podrodina B $x imunologie $7 D055651
650    _2
$a experimentální nádory $x imunologie $7 D009374
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šímová, Jana $7 xx0119399 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
700    1_
$a Bieblová, Jana $7 xx0127729 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
700    1_
$a Bubeník, Jan, $d 1940- $7 jk01020086 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
700    1_
$a Reiniš, Milan $7 xx0083033 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 25, č. 1 (2011), s. 281-288
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21109988 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160324174038 $b ABA008
999    __
$a ok $b bmc $g 949304 $s 784608
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 25 $c 1 $d 281-288 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...